FDA Pulmonary/Rheumatology Division Sees Management Shakeup
Executive Summary
Deputy Director for Safety Sally Seymour will become interim director of US FDA's Pulmonary, Allergy and Rheumatology Products Division following departure of division's top two managers, Badrul Chowdhury and Lydia Gilbert McClain.
You may also be interested in...
US FDA Office Of Immunology Turnover Tests Updated Review Structure
A leadership transition in FDA’s Office of Immunology & Inflammation will elevate former rheumatology division Director Nikolay Nikolov to the top spot – with a number of interim and inexperienced leaders in the management layers below.
US FDA Hiring For Senior Staff Vacancies Boosted By Cures Act, Pilot Program – Gottlieb
Recent departures are 'business as usual' at the agency, Commissioner says.
New OND Director Could Be Hired Within Six Months, Woodcock Says
US FDA's Office of New Drugs has been without a permanent director for more than a year as it undergoes a significant restructuring.